NCT03201042 (LyTIC) is a clinical trial of PCR based assay in Lyme Disease, sponsored by Oxford Immunotec.

Who is sponsoring NCT03201042?

NCT03201042 is sponsored by Oxford Immunotec.

What drugs are being tested in NCT03201042?

Interventions in NCT03201042: PCR based assay, Serology based assay, Tcell based assay.

What condition does NCT03201042 study?

NCT03201042 studies Lyme Disease.

Is NCT03201042 still recruiting?

NCT03201042 is currently terminated. Last updated 13 December 2018.

Last reviewed 2018-12-13 · How we verify

NCT03201042: LyTIC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Lyme Test Indication Combinations (LyTIC) Study

Terminated Last updated 13 December 2018

What this trial tests

trial testing PCR based assay in Lyme Disease in 410 participants. Terminated before completion.

Timeline

8 June 2017

Primary endpoint
30 November 2018

30 November 2018

Quick facts

Lead sponsor	Oxford Immunotec
Status	Terminated
Study type	OBSERVATIONAL
Enrollment	410
Start date	8 June 2017
Primary completion	30 November 2018
Estimated completion	30 November 2018
Sites	60 locations across United States

Drugs / interventions tested

PCR based assay
Serology based assay
Tcell based assay

Conditions studied

Lyme Disease — all drugs for Lyme Disease →

Sponsor

Oxford Immunotec

Who can join

5 and older, any sex, with Lyme Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To establish performance of individual tests and combinations of tests (serological, molecular and cellular tests) in early Lyme infection diagnosis

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Lyme Disease

Currently open trials in the same condition.

NCT06045416 — Borrelia B-cell Diagnostics · recruiting
NCT06397794 — Navigating Pregnancy and Parenthood With Lyme Disease · recruiting
NCT05477524 — An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Dise · Phase 3 · active not recruiting
NCT05036707 — Human Immune Response to Ixodes Scapularis Tick Bites · Phase 1, PHASE2 · recruiting
NCT04402086 — Rheumatology Patient Registry and Biorepository · recruiting

Other Oxford Immunotec trials

Trials by the same sponsor.

NCT04141982 — Clinical Concordance Evaluation of T-SPOT®.TB Assay Performance (T-Cell SelectTM Study) · completed
NCT03973970 — Assessing the Ability of the T-SPOT®.TB Test (IQ) · completed
NCT03929705 — Assessing the Ability of the T-SPOT®.TB Test · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03201042 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Oxford Immunotec
Last refreshed: 13 December 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03201042.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing